DiaMedica Therapeutics Inc. · NASDAQ:DMAC

DiaMedica Therapeutics Inc. financial statements

DiaMedica Therapeutics Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000500.0K00
Cost of revenue39.0K30.0K25.0K24.0K21.0K21.0K04.00K2.21K
Gross profit-39.0K-30.0K-25.0K-24.0K-21.0K-21.0K500.0K-4.00K-2.21K
Research and development24.6M19.1M13.1M7.84M8.77M8.21M7.90M4.52M3.21M1.76M
Selling, general and administrative9.78M7.62M8.16M6.16M4.88M4.49M3.69M2.74M1.31M718.0K
Operating income-34.4M-26.7M-21.3M-14.0M-13.6M-12.7M-11.6M-6.76M-4.52M-2.48M
Depreciation and amortization43.0K39.0K30.0K25.0K24.0K21.0K21.0K15.0K4.00K2.21K
EBITDA-34.4M-26.6M-21.2M-14.0M-13.6M-12.7M-11.6M-6.75M-4.51M-2.48M
Interest expense353.0K82.0K229.0K119.0K0048.4K
Income before tax-32.7M-24.4M-19.3M-13.6M-13.6M-12.3M-10.6M-5.65M-4.26M-2.20M
Income tax28.0K30.0K43.0K28.0K28.0K27.0K31.0K80.0K-9.00K22.3K
Net income-32.8M-24.4M-19.4M-13.7M-13.6M-12.3M-10.6M-5.73M-4.26M-2.22M
Earnings per share, basic-0.70-0.60-0.60-0.52-0.65-0.78-0.89-0.74-0.72-0.47
Earnings per share, diluted-0.65-0.78-0.89-0.74-0.72

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents15.6M3.02M4.54M4.73M4.71M7.41M3.88M16.8M1.35M1.74M
Short-term investments44.2M41.1M48.4M28.8M40.4M20.1M4.00M000
Receivables258.0K236.0K369.0K82.0K130.0K340.0K823.0K780.0K80.0K52.0K
Inventory113.0K10.0K88.0K000
Current assets60.6M44.6M53.7M33.8M45.4M27.9M8.84M18.0M1.49M1.85M
Property, plant and equipment145.0K148.0K131.0K136.0K70.0K74.0K64.0K96.0K37.0K19.4K
Goodwill000
Total assets61.4M46.3M54.2M34.4M45.6M28.1M9.05M18.3M1.80M1.87M
Accounts payable1.48M940.0K926.0K734.0K509.0K1.10M182.0K483.0K513.0K250.0K
Current liabilities5.13M5.39M2.79M2.17M1.52M2.03M1.32M1.30M1.00M627.0K
Long-term debt000
Total debt240.0K340.0K400.0K469.0K52.0K118.0K178.0K23.0K200.5K
Total liabilities5.26M5.63M3.10M2.57M1.53M2.08M1.44M1.31M1.00M627.0K
Shareholders' equity56.1M40.7M51.1M31.8M44.0M26.0M7.62M17.0M799.0K1.25M
Shares outstanding53.7M42.8M38.0M26.4M26.4M18.7M12.0M12.0M6.37M4.74M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-29.1M-22.1M-18.7M-11.5M-12.3M-9.19M-9.10M-5.70M-3.90M-3.02M
Capital spending-40.0K-25.0K-24.0K-81.0K-22.0K-47.0K-2.00K-50.0K-22.0K-6.89K
Free cash flow-29.1M-22.1M-18.8M-11.6M-12.3M-9.23M-9.10M-5.75M-3.92M-3.03M
Cash from investing-2.19M8.56M-18.3M11.5M-20.5M-16.1M-3.91M-50.0K-22.0K-6.89K
Cash from financing43.9M12.0M36.8M-6.00K30.1M28.8M70.0K21.2M3.54M4.59M
Dividends paid000
Share buybacks28.9M75.0K21.2M3.54M4.59M
Change in cash12.6M-1.52M-185.0K21.0K-2.70M3.53M-12.9M15.5M-383.0K1.57M